Background Preterm birth (PTB) is the leading cause of infant death, but it is unclear which intervention is best to prevent it.
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Background Preterm birth (PTB) is the leading cause of infant death, but it is unclear which intervention is best to prevent it. Objectives To compare progesterone, cerclage and pessary, determine their relative effects and rank them.
Search strategy We searched Medline, EMBASE, CINAHL, Cochrane CENTRAL and Web of Science (to April 2016), without restrictions, and screened references of previous reviews.
Selection criteria We included randomised trials of progesterone, cerclage or pessary for preventing PTB in women with singleton pregnancies at risk as defined by each study.
Data collection and analysis We extracted data by duplicate using a piloted form and performed Bayesian random-effects network meta-analyses and pairwise meta-analyses. We rated evidence quality using GRADE, ranked interventions using SUCRA and calculated numbers needed to treat (NNT).
Main results We included 36 trials (9425 women; 25 low risk of bias trials). Progesterone ranked first or second for most outcomes, reducing PTB < 34 weeks [odds ratio (OR) 0.44; 95% credible interval (CrI) 0.22-0.79; NNT 9; low quality], <37 weeks (OR 0.58; 95% CrI 0.41-0.79; NNT 9; moderate quality), and neonatal death (OR 0.50; 95% CrI 0.28-0.85; NNT 35; high quality), compared with control, in women overall at risk. We found similar results in the subgroup with previous PTB, but only a reduction of PTB < 34 weeks in women with a short cervix. Pessary showed inconsistent benefit and cerclage did not reduce PTB < 37 or <34 weeks.
Introduction
Globally, preterm birth (PTB), i.e. birth before 37 weeks of gestation, affects 15 million pregnancies yearly 1 and is a major cause of mortality 1 and morbidity in children. 2 For women at risk, individual meta-analyses have shown that progesterone, cervical cerclage and cervical pessary are each effective in reducing PTB relative to placebo or standard care. [3] [4] [5] However, to date no randomised controlled trial (RCT) has directly compared the three interventions. Hence, uncertainty exists among clinicians on the best method to prevent PTB, and various national guidelines recommend progesterone and cerclage for the same groups of at-risk women. [6] [7] [8] [9] [10] [11] [12] In the absence of an RCT directly comparing all interventions, a network meta-analysis provides the best evidence about the most effective intervention. 13 Network meta-analysis allows head-to-head comparisons of interventions indirectly through a common comparison group and subsequent ranking of the interventions. To date, this method has not been applied to study all three interventions for PTB prevention. Our objective was to determine which of these interventions, progesterone, cerclage and pessary, is the most effective for preventing PTB in women with singleton pregnancies at risk but without symptoms of labour.
Methods
We registered our protocol with PROSPERO (CRD420 15016166).
Information sources and search strategy
We searched Medline, EMBASE, CINAHL, Cochrane Central Register of Controlled Trials and ISI Web of Science up to 14 April 2016, without language restrictions (see Supporting information, Table S1 ). In addition, we screened reference lists of systematic reviews.
Eligibility criteria
Given that many women have multiple risk factors, including both previous PTB and short cervix, 14 we began with an initial broad definition of the target population as women 'at risk' for PTB as defined by the trials' authors. Specific clinical populations, such as women with previous PTB and/or short cervix, were to be explored in subgroup analyses. We included RCTs comparing interventions for preventing PTB in women at risk with either a control group or another intervention. Interventions of interest were either type of progesterone (natural progesterone per vagina or oral, or intramuscular 17a-hydroxyprogesterone caproate ), cerclage (McDonald or Shirodkar), or pessary. We excluded all other study designs including cluster-randomised trials, non-peer reviewed literature, and studies including, but not stratifying for, multiple pregnancies (twin pregnancies were synthesised in a separate study), 15 published only as abstracts, or treating women with contractions (i.e. tocolytics). Women conceiving after artificial reproductive therapy were not included (as initially considered in the protocol), because the origin of their increased risk of PTB has not yet been fully elucidated and may be partially due to elements such as the fertility treatments that are not responsive to the preventive measures.
Primary outcomes were PTB at <34 and <37 weeks of gestation, overall and stratified into spontaneous PTB.
Infant secondary outcomes included: mortality (neonatal death [NND] , perinatal death, miscarriage and stillbirth), PTB (<24, <28, <30 and <32 weeks of gestation), gestational age at birth, low birthweight (<2500 g), different definitions of small-for-gestational-age (<10th, <5th and <3rd percentile for gestational age and sex), birthweight, admission and length of stay in the neonatal intensive or special care unit (NICU), morbidities related to prematurity (respiratory problems, intraventricular haemorrhage, periventricular leucomalacia, necrotising enterocolitis, retinopathy of prematurity, sepsis), congenital anomalies, masculinisation of female fetuses, umbilical cord pH <7.1, and low Apgar score (<7) at 5 minutes. Shortly after data collection started we decided to also record very low birthweight (<1500 g) and any other definition of PTB. Medically indicated PTB was considered not relevant in this context and was not studied, although it was initially included in the protocol.
Maternal secondary outcomes were: mortality, preterm premature rupture of membranes (PPROM), intervention side effects, length of inpatient antepartum stay, number of outpatient visits and caesarean section.
Data extraction and assessment of risk of bias
Two reviewers (AJ and OL) independently screened titles and abstracts, and the full text of potentially relevant papers. Disagreements were resolved by discussion or a third assessor (SM). We contacted authors of original studies for confirmation of inclusion criteria if necessary.
Two reviewers (AJ and either OL or CP) used a piloted data collection form to independently extract data on study characteristics, potential effect modifiers, outcomes and risk of bias (using the Cochrane Risk of Bias tool). 16 We extracted raw data (e.g. 2-by-2 tables or means and standard deviations) or effect sizes (e.g. OR or mean differences) and confidence intervals.
Data synthesis and statistical analyses
For the main analyses we began with an initial broad definition of women 'at risk' of PTB, and then went on to specific clinical populations (previous PTB and/or short cervix). Although it has been suggested that women with previous PTB and women with short cervix are two distinct populations and should not be pooled together, in fact, many women have both of these risk factors. 14 We performed Bayesian random-effects network metaanalyses. 17 We obtained the pooled estimates using the Markov Chain Monte Carlo method, specifying vague prior distributions for intervention effects and assuming common heterogeneity parameters across each network. The Markov Chain Monte Carlo method is a computational simulation approach that uses both observed data and previous information to generate relative treatment effect estimates along with the corresponding 95% credible intervals (95% CrI). In addition, it also ranks the interventions by their probability of being the best, second best, etc. for each outcome. We used 100 000 iterations with a burn-in of 4000 iterations, using four chains and a thinning interval of ten. Convergence was assessed using the Gelman and Rubin's convergence diagnostic criteria. 18 The reported relative intervention effects were the posterior median odds ratios (OR) for binary outcomes and median mean differences (MD) for continuous outcomes. When there were too few studies reporting an outcome to reliably perform a network meta-analysis (an arbitrary cut-off number of ten studies was used) we performed standard pairwise inverse variance random effects meta-analyses (DerSimonian and Laird). Each measure was accompanied by its 95% credible interval (CrI, in network meta-analyses) or 95% confidence interval (CI, in pairwise meta-analyses), the numberneeded-to-treat (NNT, calculated, if statistically significant, using the estimated effect size and the pooled prevalence in the control group 16 ) , and its quality rating (assessed following the Grading of Recommendations Assessment, Development and Evaluation [GRADE] Working Group approach for network meta-analyses 19 ). The credible interval is the equivalent of the confidence interval in the Bayesian framework and, as the confidence interval, indicates a statistically significant effect if it excludes the null effect. The NNT indicates how many women at risk would need to be treated to prevent one adverse outcome. Therefore, the lower the NNT, the more effective an intervention is. The quality rating reflects certainty that the results are close to the true effect. Therefore, higher quality ratings are desirable.
Network meta-analysis relies on three basic assumptions. First, as in pairwise meta-analyses, it assumes that studies comparing interventions head to head (direct estimates) are similar (absence of heterogeneity). Second, when calculating indirect estimates, it assumes that the direct comparisons on which they are based have a comparable set of studies (transitivity). Third, a network meta-analysis assumes that the direct and indirect estimates between pairs of interventions are similar (coherent). We quantified heterogeneity in the direct comparisons using I 2 (we did not test for heterogeneity using the chi-squared test or Q test), 20 and assessed intransitivity by comparing the studies across each of the direct comparisons in terms of risk factors and baseline characteristics. Incoherence between the direct and indirect effect estimates was assessed using the node-splitting method. 21 When the assumptions are challenged, the results of the network meta-analysis might be limited. These limitations were operationalised using the GRADE approach for network meta-analysis, which, among other aspects such as risk of bias of the studies, takes into consideration these assumptions to rate the quality of the evidence, downgrading its rating if there is heterogeneity, intransitivity or incoherence. 19 For the outcomes where a network meta-analysis was performed the interventions were ranked according to their Surface Under the Cumulative RAnking curve values (SUCRA), which reflect the likelihood of an intervention of being among the best. 22 Higher SUCRA values indicate higher probabilities of an intervention consistently being among the best. The statistical software R was used for network meta-analyses ('GEMTC' package 23 ) and REVIEW MAN-AGER (v.5.3) was used for pairwise meta-analyses. Publication bias was assessed using funnel plots and Duval and Tweedie's trim-and-fill method (when there were at least ten studies and funnel plot showed asymmetry).
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Subgroup and sensitivity analyses
We planned subgroup analyses for primary outcomes by indication for PTB prevention, i.e. previous PTB or short cervix. However, most of the original studies did not fit this exclusive classification. Hence, although all women in the previous PTB subgroup have this risk factor in common, other risk factors are not excluded. Similarly, all women in the short cervix subgroup have a cervical length ≤25 mm, but not to the exclusion of other risk factors.
Other subgroup analyses were by type of progesterone (network comparing natural progesterone versus 17-OHPC versus cerclage versus pessary versus control) and type of cerclage [progesterone (either type) versus McDonald cerclage versus Shirodkar cerclage versus pessary versus control]. Other planned subgroup analyses included parity, cervical insufficiency and infant sex. Sensitivity analyses were planned for low risk of bias. Subgroups by type of progesterone were considered more clinically relevant than route of administration, as was initially planned. 26 In a network meta-analysis all the direct comparisons of the network are assumed to have a similar heterogeneity (Τau square, quantified as I 2 ) and a common value is therefore used for the whole network. However, in several of our analyses we found that the direct comparisons had differing I 2 , resulting in overly wide (or narrow) credible intervals. In addition, in some analyses the transitivity assumption (comparability of sets of studies on baseline characteristics) was challenged. Therefore, the results of the network meta-analyses were compared with pairwise metaanalyses (post hoc). Further post hoc analyses were subgroup analyses by indication for PTB prevention for NND, a key secondary outcome.
Results
Of 12 928 references initially identified, 4420 duplicates were deleted, 8304 were excluded based on titles and abstracts and 99 were added from previous systematic reviews. We assessed 303 full-text articles, of which 36 met the inclusion criteria, totalling 9425 women (see Supporting information, Figure S1 ).
Study characteristics
A control group of usual care or placebo was compared with progesterone (either type) in 17 studies, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] with cerclage in 12 studies [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] and with pessary in three studies. [56] [57] [58] In addition, one study compared 17-OHPC with cerclage 59 and three studies compared natural progesterone with 17-OHPC [60] [61] [62] (Table 1 , and see Supporting information, Figure S2 ).
Only one study included women with only a short cervix (excluding women with previous PTB) 57 and only one study included women with only previous PTB (excluding women with a short cervix). 45 In all of the remaining 34 studies, women were defined as being 'at risk' in a variety of ways, without targeting a specific group: 21 studies included previous PTB, or short cervix or both, but without excluding the other, while 13 studies had inclusion criteria beyond these. In studies including women with short cervix, but not excluding women with previous PTB, the prevalence of this risk factor, when reported, ranged from 11% to 80% (median 16%).
Almost half of the studies were from middle-income countries, but none were from low-income countries. 63 Twenty-five studies had low risk of bias (see Supporting information, Figure S3 and Appendix S1). Individual study data for each outcome are shown in the Supporting information (Figures S4.1 to S4.59).
Primary outcomes
Progesterone (either type) was the only intervention that significantly reduced the odds of both PTB < 34 weeks (OR 0.44; 95% CrI 0.22-0.79; NNT 9; low quality of evidence) and PTB < 37 weeks (OR 0.58; 95% CrI 0.41-0.79; NNT 9; moderate quality), compared with control. Progesterone reduced PTB < 34 weeks in studies that specifically labelled it as spontaneous (OR 0.48; 95% CI 0.27-0.85; NNT 9; low quality). Pessary reduced PTB < 37 weeks overall (OR 0.30; 95% CrI 0.13-0.76; NNT 5; very low quality) and spontaneous PTB < 37 weeks in one study (OR 0.19; 95% CI, 0.12-0.29; NNT 3; low quality). In none of the network meta-analyses was significant incoherence detected. Further details are shown in the Supporting information (Tables 2, S2 .1 and S2.2).
Secondary outcomes
Progesterone (either type) significantly reduced NND (OR 0.50; 95% CrI 0.28-0.85; NNT 35; high quality), PTB < 32 weeks (OR 0.59; 95% CrI 0.33-0.93; NNT 17; low quality), NICU admission (OR 0.38; 95% CrI 0.13-0.91; NNT 7; very low quality), and increased gestational age at birth (MD 1.21 weeks; 95% CrI 0.27-2.18; moderate quality), compared with control. Cerclage increased gestational age at birth (MD 1.38 weeks; 95% CrI 0.10-2.71; very low quality) and pessary reduced PPROM (OR 0.33, 95% CrI 0.13-0.82; NNT 12; very low quality). Other secondary outcomes are shown in Table 2 and detailed in the Supporting information (Tables S2.3 to S2.18).
Pairwise meta-analyses
For outcomes with fewer than ten studies we performed pairwise meta-analyses rather than network meta-analyses. Progesterone (either type) reduced PTB < 33 and <35 weeks, very low birthweight (<1500 g), perinatal death, respiratory distress syndrome and early onset of sepsis (<72 hours), compared with control. Cerclage reduced PTB <24 and <33 weeks and perinatal death (Figure 1 ). Other variably reported outcomes not amenable to meta-analysis, and outcomes lacking data, are summarised in the Supporting information (Tables S3.1 
and S3.2).
Subgroup analyses
In the subgroup of women with previous PTB (cervical length was not considered in most of these studies, ten using progesterone, three using cerclage), progesterone (either type) significantly reduced PTB < 34 weeks (OR 0.39; 95% CI 0.22-0.70; I 2 0%; NNT 7; moderate quality), PTB < 37 weeks (OR 0.43; 95% CrI 0.24-0.72; NNT 6; moderate quality), and NND (OR 0.50; 95% CI 0.27-0.93; I 2 0%; NNT 43; moderate quality). No study assessed pessary in this subpopulation and the few studies assessing cerclage found no significant effect on PTB < 37 weeks or NND (Table 3 ). The only study including women with previous PTB and without a short cervix compared cerclage with control, finding no significant effect on PTB < 37 weeks (see Supporting information, Figure S4 .7) or NND (see Supporting information, Figure S4 .9). 45 In women with a short cervix (≤25 mm) in the current pregnancy (previous PTB was not considered in most of these studies, four using progesterone, four cerclage, two pessary and one comparing cerclage with progesterone), (Table 3 ). The only study including women with a short cervix (≤25 mm) and without a previous PTB compared pessary with control and found no significant effect on PTB < 34 weeks, PTB < 37 weeks or NND (see Supporting information, Figures S4,11 , S4.13, and S4.15). 57 In the one study including only women with both previous PTB and short cervix (≤25 mm), cerclage significantly reduced PTB < 37 weeks (OR 0.52; 95% CI 0.29-0.90). 54 When progesterone was studied according to type of progesterone (either natural progesterone [per vagina or oral] or 17-OHPC), only natural progesterone significantly reduced PTB < 34 weeks (OR 0.38; 95% CrI 0.19-0.69; NNT 8; low quality; Table 3 ). Both natural progesterone and 17-OHPC significantly reduced PTB < 37 weeks (natural progesterone, OR 0.54; 95% CrI 0.36-0.76; NNT 8; moderate quality; 17-OHPC, OR 0.65; 95% CrI 0.42-0.96; NNT 11; moderate quality). There were no statistically significant subgroup differences between natural progesterone and 17-OHPC for either PTB < 34 weeks (P = 0.25) or <37 weeks (P = 0.48).
When cerclage was studied according to its type, neither the Shirodkar nor the McDonald cerclage significantly reduced PTB < 34 or <37 weeks (Table 3) .
In studies with low risk of bias, the lower odds of PTB < 34 weeks with progesterone were no longer significant (OR 0.58; 95% CrI 0.29-1.07). However, the results for PTB < 37 weeks were similar to those in the full analysis, with significantly lower odds in women receiving progesterone or pessary (Table 3) .
No study reported data stratified by parity, cervical insufficiency or infant sex.
Sensitivity analyses
In several of our analyses we found that the meta-analyses of the direct comparisons had high I 2 values (e.g. 86% for pessary in PTB < 34 weeks). Furthermore, for the same outcomes, the heterogeneity varied for each intervention (e.g. 6% for cerclage, 55% for progesterone and 86% for pessary), which could lead to overly wide (or narrow) credible intervals in the network meta-analysis. Therefore, we compared the results of the network meta-analyses with pairwise meta-analyses and found similar results and conclusions for most outcomes. However, some conclusions differed, including for PTB < 37 weeks (pessary was no longer statistically significant), PTB < 28 weeks (progesterone and pessary became statistically significant), PPROM (pessary was no 47 Only outcomes not reported in Rust et al. 47 were used. Three women in the cerclage group were offered a revision procedure, and one woman in the no-cerclage group received a rescue cerclage.
#
Only women not receiving progesterone were included. **It was not specified if intramuscular progesterone was 17-OHPC, as was in all other studies using this route of administration. After unsuccessfully asking for clarification from the pharmaceutical company, we assumed it to be 17-OHPC. † † Reported as vaginal progesterone; we assumed it was natural progesterone.
longer statistically significant), and birthweight (cerclage and progesterone became statistically significant). In addition, in studies with low risk of bias assessing progesterone, PTB < 34 weeks became statistically significant when analysed in a pairwise meta-analysis (Tables 2  and 3 , and see Supporting information, Table S4 ). Publication bias was not suspected for most outcomes when examining their funnel plots. However, possible publication bias was suggested in the meta-analyses of progesterone versus control for PTB < 34 weeks (trim and fill method adjusted OR 0.67, 95% CI 0.44-1.03 versus OR 0.44; 95% CrI 0.22-0.79).
Mechanical ventilation
Discussion
Main findings
In this first comprehensive network meta-analysis, a fairly new method for ranking and comparing interventions for preventing PTB in women at risk, progesterone appeared to be the best option. Progesterone ranked higher than cerclage for most of our outcomes and was associated with significantly lower odds of PTB < 34 weeks, PTB < 37 weeks, and NND, among others. Similar results were found in the subgroup of women with previous PTB, but not in women with a short cervix, where scant evidence suggested lower odds of only PTB < 34 weeks. For pessary, there were inconsistencies in rankings and very low quality of evidence overall.
Strengths and limitations
Among the strengths of this study was its rigorous methodology for performing direct and indirect comparisons and combining them in a network estimate whenever possible, which has not been done before. This allowed us to compare interventions even when there were few or no direct comparisons in the literature. Interventions could be ranked and their probability of being among the best could be calculated. Regarding the three key assumptions underlying network meta-analysis, we quantified heterogeneity with I 2 , assessed incoherence with node-splitting, and evaluated intransitivity by comparing studies on several potential effect modifiers. Furthermore, we used the GRADE approach for network meta-analysis, integrating the assessment of heterogeneity, incoherence and intransitivity in a quality rating that reflects the confidence in the results of each network meta-analysis, facilitating a more comprehensive interpretation.
Another strength of our study is our initial broad approach to the analyses targeting women 'at risk' of PTB, which reflects the heterogeneous samples in the original included studies, and which also reflects the real clinical world in which women are prescribed interventions for a variety of indications. Almost none of the studies are limited to exclusive groups of women with either a previous PTB or a short cervix, despite the tendency for previous systematic reviews and guidelines to suggest this. For example, pooling studies with up to 80% prevalence of previous PTB under the label 'short cervix' can generate an illusion of homogeneity that does not correspond to the actual heterogeneity of the samples. To try to avoid this, we carefully specified that all women in the previous PTB subgroup have this common risk factor, but other risk factors are not excluded. Similarly, all women in the short cervix subgroup have a cervical length ≤25 mm, but not to the exclusion of other risk factors. Although it has been argued that women with a previous PTB and women with short cervix are two distinct populations, approximately one in five women with previous PTB has a short cervix.
14 Additionally, in the studies included in this systematic review, the reported prevalence of previous PTB in women with a short cervix ranged from 11% to 80%. In consequence, we believe that the optimal approach to this topic is to begin by targeting women 'at risk' of PTB, and then focus on specific clinical populations (previous PTB or short cervix), being aware of the heterogeneity in the original studies.
This study has several limitations. First, it was limited by the data reported in the included studies, as we considered the peer review process to be a key prerequisite. Second, there was scant data on short cervix, pessary, and directly comparing interventions. Consequently, the credible and confidence intervals were very wide in some of the analyses, without statistically significant effects. Third, there was no data from low-income countries and caution is advised when extrapolating the results to these countries, although markedly different results are not anticipated. Fourth, there may be publication bias in the progesterone arm of our network for PTB < 34 weeks. Fifth, many of our meta-analyses included a small number of studies, a scenario that remains challenging for random effects meta-analysis (both using the DerSimonian-Laird and the Knapp-Hartung methods), and for which no clear guidance exists. 64 Finally, any network meta-analysis is based on three assumptions: absence of heterogeneity, transitivity and coherence. Although significant incoherence was not found, heterogeneity and/or intransitivity was detected in several of the networks. This is an important limitation of the results, although one that was assessed using the GRADE approach. 19 Although this resulted in several 'low' and 'very low' quality of evidence assessments, which should be interpreted accordingly, it also gives confidence in results assessed as moderate and high quality of evidence.
Interpretation in light of other evidence
To our knowledge, there has been no other network metaanalysis comparing progesterone, cerclage and pessary for the prevention of PTB. One review did an indirect comparison meta-analysis of vaginal progesterone and cerclage, 65 but did not combine the direct and indirect estimates or assess the probability of each intervention being the best. Our findings of reductions in PTB < 34 and <37 weeks and NND with progesterone are consistent with the previous individual systematic review on progesterone, although our findings on cerclage, with the inclusion of additional studies, differed from the previous meta-analysis, which included unpublished data 4 and in which a significant effect of cerclage in preventing PTB < 34, <37 and <28 weeks was found. Our findings for pessary, based on three studies, differed from the previous individual systematic review of one study. Overall, nine studies were included in this review that were not present in previous reviews [41] [42] [43] 55, 57, 58, [60] [61] [62] , including the largest studies to date on progesterone and pessary. 43, 58 Studies included in previous reviews that we excluded are listed in the Supporting information (Table S5 ).
Conclusions
In this network meta-analysis, progesterone (particularly natural progesterone) appeared to be the best intervention over pessary and cerclage for primary prevention of PTB in at-risk women with a singleton pregnancy, particularly in women with a previous PTB. Although the quality of evidence ranged from very low to high, progesterone decreased PTB < 34 weeks, <37 weeks and many other sequelae of PTB including neonatal demise. Further trials are required including women with short cervix, assessing pessary, comparing interventions directly with each other, and studying combinations of interventions. In the mean time, the rankings and summary estimates in our network meta-analysis showed that progesterone is better than cerclage or pessary for PTB prevention. influence on the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
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